Furthermore, a randomized controlled trial showed that Canakinumab lowers IL-1β among patients with a previous myocardial infarction, leading to a reduced risk of experiencing cardiovascular events10 and of lung cancer incident and mortality2. The gene discussed is IL1B; the disease is lung carcinoma.